Cultivating innovation post acquisition: Bayer and Vividion’s arm’s length model

1:00 PM - 2:00 PM (PDT), Monday, June 13, 2022 ・ Upper Level, Session Room 3

When Vividion examined the next steps for their company, an IPO was the path forward. Until one day, Bayer called and plans changed. What has happened since then and how have the two companies worked to foster innovation and collaboration? Join Dr. Marianne De Backer, Chief Business Officer, for the Pharmaceuticals division of Bayer and Jeff Hatfield, CEO, Vividion, for a candid discussion about the arm’s length model, innovation, and advancements in the undruggable space.

Sponsored By
Chief Editor
Life Science Leader Magazine
EVP, Head of Business Development and Licensing
Bayer Pharmaceuticals
Vividion Therapeutics